Your 23andMe Results Are In. Here's What They Actually Mean.

APOE encodes a protein that your body uses to carry cholesterol throughout your bloodstream and into your brain. Your cells need cholesterol to build and repair neural membranes, so APOE is essential to brain structure and function. It also plays a role in clearing amyloid-beta, the sticky protein that accumulates in Alzheimer’s disease.

You have two copies of the APOE gene (one from each parent), and each copy can be one of three variants: E2, E3, or E4. The E4 variant, carried by roughly 25-30% of people with European ancestry, produces a form of APOE that carries cholesterol less efficiently and clears amyloid-beta more slowly. People with one or two E4 copies have significantly elevated lifetime risk for cognitive decline and Alzheimer’s disease, though inheritance is not destiny.

If you carry E4, your brain’s ability to clear toxic proteins slows down, and your cholesterol management shifts. You’re not guaranteed to develop Alzheimer’s, but your brain will benefit more from proactive interventions than someone with E2 or E3. Standard cholesterol targets may not be sufficient for you. Your risk window is longer.

MTHFR is an enzyme that your cells need to convert dietary B vitamins (particularly folate) into their active, usable form. This conversion is the first step in a chain of reactions that your cells use to produce energy, build neurotransmitters, repair DNA, and regulate inflammation. Without adequate MTHFR activity, your cells are trying to run on incomplete fuel.

The C677T variant, carried by roughly 40% of people with European ancestry, reduces MTHFR enzyme efficiency by 40-70%. You can eat a perfect diet and still be functionally depleted at the cellular level because your body cannot convert the B vitamins you’re consuming into the forms your cells can actually use. This means your energy production, neurotransmitter synthesis, and DNA repair are all running at a fraction of the rate they should be.

If you carry this variant, you’ve probably noticed fatigue that doesn’t match your sleep or activity level, brain fog that improves unpredictably, or a tendency toward mood instability. You may have tried standard B vitamins with little effect. That’s because your cells need the pre-converted, methylated forms that bypass the broken conversion step entirely.

BRCA1 is a tumor suppressor gene that your cells use to repair DNA damage before it can accumulate and turn into cancer. Every day, your cells experience thousands of DNA breaks from normal metabolism, UV exposure, and oxidative stress. BRCA1 proteins are the cleanup crew that finds these breaks, flags them, and repairs them accurately before cells divide. Without functioning BRCA1, damaged DNA gets passed down to daughter cells, increasing the odds of mutation and malignant transformation.

BRCA1 pathogenic variants (loss-of-function mutations) are relatively rare, found in roughly 1 in 300 to 1 in 500 people of European ancestry, though rates are higher in Ashkenazi Jewish populations. People with BRCA1 pathogenic variants have a 45-87% lifetime risk of breast cancer and a 40-50% risk of ovarian cancer, depending on the specific mutation and other factors. This is substantially higher than the general population risk of 12% for breast cancer and 1.3% for ovarian cancer.

If you carry a BRCA1 variant, cancer risk is real and significant, but it is not inevitable. Your cells have time to accumulate damage, and many interventions can slow that accumulation. Screening, prevention, and lifestyle modification all matter. This is not a death sentence; it is actionable biological information.

BRCA2, like BRCA1, is a tumor suppressor gene responsible for repairing DNA damage before it accumulates into cancer. BRCA2 mutations follow a similar inheritance pattern and carry similar clinical implications. Both proteins work in the same repair pathway; they’re essentially backup systems for each other, which is why mutations in either one increase cancer risk substantially.

BRCA2 pathogenic variants occur in roughly 1 in 300 to 1 in 500 people of European ancestry. People with BRCA2 mutations have a 45-85% lifetime risk of breast cancer and a 15-20% risk of ovarian cancer. Men with BRCA2 variants also face elevated prostate cancer risk (20-40% lifetime). The specific mutation, family history, and other genetic modifiers determine where you fall within that range.

If you carry a BRCA2 variant, your cells’ ability to catch and fix DNA errors is compromised. But screening, prevention, and targeted lifestyle changes can catch cancers early and slow tumor development. This is actionable biology, not destiny. Medical surveillance and risk reduction become central parts of your health plan.

CYP2D6 is one of your liver’s primary enzyme systems for breaking down medications. It metabolizes roughly 25% of all pharmaceuticals commonly prescribed, including antidepressants, pain relievers, blood pressure medications, cancer drugs, and antiarrhythmics. Your body needs to convert these medications into inert forms so they can be excreted safely. If your CYP2D6 is slow, medications accumulate to toxic levels. If it’s fast, they clear before they can work.

CYP2D6 comes in many variants, ranging from complete gene deletion (ultrafast metabolizer) to nonfunctional copies (poor metabolizer). Roughly 7-10% of people of European ancestry are poor metabolizers, meaning they have minimal or zero CYP2D6 activity. Poor metabolizers experience toxic accumulation of standard doses of CYP2D6 substrates, leading to severe side effects, while fast metabolizers experience no benefit because the medication clears too quickly. A standard dose that helps most people can be dangerous for you or useless, depending on your CYP2D6 status.

If you’ve had unexpected medication side effects, felt nothing from a medication that should have worked, or been labeled “treatment-resistant,” your CYP2D6 status may be the missing piece. Your doctor prescribed a standard dose based on average genetics. Your genetics are not average.

VDR is a receptor protein that your cells use to respond to vitamin D. Vitamin D enters cells, binds to VDR, and signals your cells to do critical things: absorb calcium, regulate immune response, control inflammation, and generate energy in your mitochondria. VDR is present in nearly every cell in your body because vitamin D’s effects are nearly universal. Your bones, immune system, brain, and mitochondria all depend on functional VDR.

VDR comes with several common variants (BsmI, FokI, TaqI), carried by roughly 30-50% of people. Certain VDR variants reduce your cells’ ability to sense and respond to vitamin D, meaning you need higher circulating levels of vitamin D to achieve the same biological effect as someone with the ancestral variant. Even if your blood vitamin D level looks normal on standard lab ranges, your cells may be functionally deficient because they cannot uptake or respond to it efficiently.

If you carry a VDR variant, you’ve probably noticed that standard vitamin D supplementation (1000-2000 IU daily) doesn’t shift how you feel, or that your energy and immune function remain sluggish even when your vitamin D blood levels are in range. Your cells are essentially vitamin D-blind. They need either much higher circulating levels or more frequent dosing to sense the signal.